REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot126310.21518/1561-5936-2018-6-34-42Original ArticleRational drug therapy of ulcerative colitis: meta-analysis and clinical and economic aspects of modern therapy regimensShatalovaO. V.noemail@neicon.ruGorbatenkoV. S.noemail@neicon.ruVolgograd State Medical University061220186344218032022Copyright © 2018,2018Ulcerative colitis (UC) is an idiopathic chronic relapsing inflammatory disease of the large intestine, leading to disability of working-age people [1-3]. Due to the growth of urbanization and economic development, there is a rapid increase in the incidence of UC in the industrialized countries. According to the forecasts, the increase in morbidity will require the restructuring of medical care to the patients with this pathology [4].Ulcerative colitismeta-analysisclinical and economic analysispharmacoeconomic analysiscost-effectivenesscost minimizationgenetic engineering biological therapygenetically engineered biologic drugsTNF inhibitorJanus kinase inhibitoradalimumabcerolizumab pegolgolimumabinfliximabvedolizumabtofacitinibязвенный колитметаанализклинико-экономический анализфармакоэкономический анализэффективность затратминимизация затратгенно-инженерная биологическая терапияГИБПингибитор ФНО-аингибитор Янус-киназадалимумабцертолизумаба пэголголимумабинфликсимабведолизумабтофацитиниб